ライフサイエンスコーパス: vaccine strain

1 recipients were infected with gB1 genotype (vaccine strain).

2 the single-dose group (p>=0.20 for the three vaccine strains).

3 structed using the live-attenuated HSV-1 VC2 vaccine strain.

4 ies barrier and warrants selection of an H10 vaccine strain.

5 ne, mg0359, unique to M. gallisepticum ts-11 vaccine strain.

6 protein in the background of the current MV vaccine strain.

7 tion inhibition antibody titers against each vaccine strain.

8 cally distinct from the current A(H1N1)pdm09 vaccine strain.

9 significantly lower levels than against the vaccine strain.

10 eason's B/Massachusetts/02/2012-like clade 2 vaccine strain.

11 ower in mice immunized with the conventional vaccine strain.

12 against the 2009 pandemic influenza A(H1N1) vaccine strain.

13 pulmonary infection with F. tularensis live vaccine strain.

14 pulmonary infection with F. tularensis live vaccine strain.

15 e L. major strain and its potential use as a vaccine strain.

16 2016 compared with the A/Hong Kong/4801/2014 vaccine strain.

17 lla (n = 2) or zoster (n = 2) due to the Oka/vaccine strain.

18 No child shed A/H1N1 vaccine strain.

19 tion and predict the efficacy of a candidate vaccine strain.

20 ses and examples of three different types of vaccine strain.

21 t to assist in monitoring disease due to Oka-vaccine strain.

22 3c2.A and 3c2.A2 H3N2 viruses, and the H1N1 vaccine strain.

23 ortugal/79906/2009 (H10N7) as a suitable H10 vaccine strain.

24 CHMI using Pf parasites heterologous to the vaccine strain.

25 lution and extensive virus passaging to make vaccine strains.

26 berculosis drugs and attenuated tuberculosis vaccine strains.

27 dentity between the two variants and classic vaccine strains.

28 age matches with recommended influenza virus vaccine strains.

29 polymerases might serve as live, attenuated vaccine strains.

30 rt limited T cell immunity restricted to the vaccine strains.

31 rrant further development as live-attenuated vaccine strains.

32 [DISC]) strain to generate a series of DISC vaccine strains.

33 -secreting cells elicited by historical H1N1 vaccine strains.

34 tment between the G1P[5] and G6P[8] parental vaccine strains.

35 cluster that were genetically distinct from vaccine strains.

36 ere immunized at birth with one of three BCG vaccine strains.

37 proinflammatory reaction to live attenuated vaccine strains.

38 tion neutralization test (PRNT) against both vaccine strains.

39 ystems commonly used to generate and amplify vaccine strains.

40 Nashville, TN, differ markedly from those of vaccine strains.

41 ses were antigenically similar to cell-grown vaccine strains.

42 nd humoral immune responses against the four vaccine strains.

43 enza surveillance to inform the selection of vaccine strains.

44 immune system very differently than those of vaccine strains.

45 imens containing viruses representing recent vaccine strains.

46 e strain, and 15 mug of haemagglutinin per B vaccine strain) (1) by microneedle patch or (2) by intra

47 cted in 82% of specimens (84% wild-type, 15% vaccine-strain, 1% possible vaccine-wild-type recombinan

48 (fluvirin: 18 mug of haemagglutinin per H1N1 vaccine strain, 17 mug of haemagglutinin per H3N2 vaccin

49 as a model the yellow fever virus (YFV) live vaccine strain 17D-204 and its wild-type parental strain

50 for efficient CHIKV replication using CHIKV vaccine strain 181/25 and clinical isolate SL15649.

51 zation, which likely mediates attenuation of vaccine strain 181/25.

52 H3 isolates from those against egg-grown H3 vaccine strain A/Texas/50/2012 (TX/12e).

53 he notable exception of the responses to the vaccine strain A244 Env that were dominated by V2, where

54 f attenuation of the Sabin 2 oral poliovirus vaccine strain (A481 in the 5'-untranslated region [5'-U

55 the clinical-like strain TB40-BAC4 or to the vaccine strain AD169varATCC, prior to their long-term ma

56 able to detect RNA from five currently used vaccine strains, AIK-C, CAM-70, Edmonston-Zagreb, Morate

57 o achieved in cattle with a mixture of three vaccine strains, albeit at a lesser level than in sheep.

58 magglutinin glycoprotein and the egg-adapted vaccine strain also bore mutations, notably T160K loss-o

59 ce glycosaminoglycans are utilized by both a vaccine strain and a clinical isolate of CHIKV to mediat

60 of A(H1N1)pdm09 viruses well-matched to the vaccine strain and A(H3N2) viruses, the majority of whic

61 ers within 1 week of delivery, regardless of vaccine strain and HIV exposure status.

62 luded B. mallei DeltatonB Deltahcp1 (CLH001) vaccine strain and investigated its ability to protect a

63 high antibody titers against the egg-adapted vaccine strain and lower titers against circulating viru

64 irculate in the United States and from swine vaccine strains and also showed antigenic drift from hum

65 emonstrated the genetic stabilities of these vaccine strains and also the complementing cell line.

66 ive, they are affected by mismatches between vaccine strains and circulating strains.

67 drift, which can lead to mismatches between vaccine strains and circulating strains.

68 nt study to distinguish the M. gallisepticum vaccine strains and field isolates based on mutations in

69 erful framework for rational design of safer vaccine strains and for forecasting virulence of viruses

70 roadmap both for the development of improved vaccine strains and for the creation of a framework to '

71 influenza A/Hong Kong/4801/2014(H3N2) virus vaccine strains and representative circulating viruses (

72 erivatives have been used for development of vaccine strains and vaccine adjuvants.

73 h amino acid identity between the E genes of vaccine strains and wild-type viruses from trial partici

74 mumps virus vaccine strain (hereafter, the "vaccine strain") and the MuVi/Utrecht.NLD/40.10 outbreak

75 s in vaccinated children (both wild-type and vaccine-strain) and 230 per 100,000 person-years in unva

76 ne strain, 17 mug of haemagglutinin per H3N2 vaccine strain, and 15 mug of haemagglutinin per B vacci

77 following MMR-3 receipt, levels of IgG, anti-vaccine strain, and anti-outbreak strain antibodies incr

78 Using HRVs, including the Rotarix RV1 vaccine strain, and ARVs, we evaluated host susceptibili

79 red with the A/Texas/50/2012-like clade 3C.1 vaccine strain, and more than half were antigenically mi

80 st strains were antigenically similar to the vaccine strain, and no resistance or known pathogenicity

81 genome differences among vaccine revertants, vaccine strains, and field isolates, whole-genome sequen

82 y, some vaccines may revert to virulence and vaccine strains are generally difficult to distinguish f

83 More than 20 genetically distinct BCG vaccine strains are in use worldwide.

84 enough diversity to suggest updates in swine vaccine strains are needed.

85 d between the clusters to suggest updates in vaccine strains are needed.

86 accine efficacy against viruses matching the vaccine strain at V2 residue 169.

87 urvival of Salmonella enterica serovar Typhi vaccine strains at pHs 3.0 and 2.5 to compensate for the

88 were 10-60% distant from those of commercial vaccine strains at the amino acid sequence level.

89 ynthesis, was introduced into two Salmonella vaccine strains attenuated by auxotrophic traits or by t

90 is genetically distinct from the commercial vaccine strains B1 and LaSota, which belong to genotype

91 isabled infectious single-cycle (DISC) viral vaccine strain based on a guinea pig cytomegalovirus (GP

92 ss in animal models, including an attenuated vaccine strain based on an isolate from La Reunion incor

93 ncovers the evolutionary strategies by which vaccine strains become pathogenic and provides a powerfu

94 irus strains were different clades, with the vaccine strain being clade 3C.2a and the circulating vir

95 ive antibodies against not only the dominant vaccine strains but also minor circulating strains that

96 ging from 18% to 49%; p<=0.019 for the three vaccine strains), but were similar between the two-singl

97 Many children shed A/H3N2 and B vaccine strains, but none shed A/H1N1.

98 ainst plague, we developed a live-attenuated vaccine strain by deleting the Braun lipoprotein (lpp) a

99 anslational viability of the HSV-1 0DeltaNLS vaccine strain by demonstrating that, while it is compar

100 ome differs from the 1950s-era prototype and vaccine strains by a lateral gene transfer, substituting

101 ed assays enable the differentiation of live vaccine strains by targeting two or three markers/vaccin

102 The live attenuated vaccine strain Candid #1 (Can) is approved for use in re

103 e applied to identify antigenic variants and vaccine strain candidates for pathogens with rapid antig

104 We prepared a human rotavirus vaccine strain, CDC-9 (G1P[8]), which when grown in MA10

105 ly interested in the F. tularensis LVS (live vaccine strain) clpB (FTL_0094) mutant because this stra

106 to protect against seasonal infections, and vaccine strain compositions are updated every year.

107 MRC-DPRU442/2012/G1P[8], exhibited a RotaTeq vaccine strain constellation of G1-P[8]-I2-R2-C2-M2-A3-N

108 urthermore, to test if mixtures of different vaccine strains could be tolerated, we tested cocktails

109 e, nonreplicating avirulent uracil auxotroph vaccine strain (cps) of Toxoplasma triggers novel innate

110 ttenuated Vibrio cholerae O1 classical Inaba vaccine strain CVD 103-HgR, elicits seroconversion of vi

111 HAI titers of 1:40 or more to the influenza vaccine strains decreased from more than 56% in the firs

112 The growth curves of three recent vaccine strains demonstrated that the qRT-PCR signal det

113 2016, a period during which the A(H1N1)pdm09 vaccine strain did not change.

114 least 1 (ID 69% vs IM 68%; P = .7) of the 3 vaccine strains did not differ significantly between ID

115 us serotypes 1 to 4 and the yellow fever 17D vaccine strain, did not antagonize STAT5 phosphorylation

116 inherent difficulties of updating influenza vaccine strains each influenza season.

117 e genetics system for the live-attenuated MV vaccine strain Edmonston-Zagreb (EZ), allowing recovery

118 We find that this vaccine strain elicits antibodies that have reduced reac

119 e tested the ability of oral M. tuberculosis vaccine strains expressing SIV Env and Gag proteins, fol

120 irus (NDV) recombinants, based on the LaSota vaccine strain, expressing glycoproteins B (gB) and D (g

121 could be engineered into a thermolabile NDV vaccine strain for developing novel thermostable NDV vac

122 variants of influenza viruses and to select vaccine strains for use in controlling and preventing di

123 le to distinguish the M. gallisepticum ts-11 vaccine strain from field isolates.

124 ches to quickly distinguish M. gallisepticum vaccine strains from field isolates.

125 o in response to Francisella tularensis Live Vaccine Strain (Ft. LVS) infection.

126 rase) deletion mutant of Ft. live attenuated vaccine strain (Ft.LVS), designated Ft.LVS::Deltawzy, wa

127 d lower than the GMTs against the Jeryl Lynn vaccine strain (genotype A).

128 Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly h

129 The RdRp of the Sabin I vaccine strain has Thr-362 changed to Ile.

130 A number of live attenuated RSV vaccine strains have been developed in which the small h

131 The mutated vaccine strain hemagglutinin binds in addition the ubiqu

132 est) against both the Jeryl Lynn mumps virus vaccine strain (hereafter, the "vaccine strain") and the

133 Vaccine-strain herpes zoster (HZ) can occur after varice

134 The reduction in vaccine strain heterogeneity following tick passage did

135 could bind infectious virions (including the vaccine strains HIV-1 CM244 and HIV-1 MN and an HIV-1 st

136 the genetic design of replication-competent vaccine strains holds the promise for a potent, broadly

137 ne strains by targeting two or three markers/vaccine strain; however, considering the high variabilit

138 lipid (FtL) from Francisella tularensis live-vaccine strain (i) induces FtL-specific B-1a to produce

139 ging G9 porcine RV strains and a human G1 RV vaccine strain in a susceptible host (swine) will allow

140 chorioallantois vaccinia virus Ankara (CVA) vaccine strain in chicken embryo fibroblasts during whic

141 onses elicited by the egg-adapted 3c3.A H3N2 vaccine strain in ferrets and humans.

142 ompared with those of the WT strains and the vaccine strain in two different murine models: infant CD

143 Shedding of RotaTeq vaccine strains in 7 of 13 infants was associated with u

144 This study assessed inactivated prepandemic vaccine strains in a One Health framework across human a

145 the immune response induced by different BCG vaccine strains in newborn infants.

146 easily adoptable method to identify measles vaccine strains in suspect cases.

147 ng strains that can evolve into the dominant vaccine strains in the future.

148 imary was seroconversion rate to each of the vaccine strains in the mothers 1 month after completion

149 eplicating, live attenuated uracil auxotroph vaccine strains in the type II Deltaku80 genetic backgro

150 viruses, including the YF and measles virus vaccine strains, in the absence or presence of exogenous

151 ell (MBC) activation, and recognition of non-vaccine strains) indicated that, overall, Vaxxas HD-MAP

152 isabled infectious single-cycle (DISC) GPCMV vaccine strain induced an antibody immune response to th

153 ensis strain SchuS4, but not attenuated live vaccine strain, inhibit inflammatory responses in vitro

154 While the vaccine strain is approved for use in regions of endemic

155 ation "bottleneck." We demonstrated that the vaccine strain is genetically heterogeneous at 46 chromo

156 at Mycobacterium bovis BCG, the tuberculosis vaccine strain, is severely deficient in HIA, and we exp

157 ule inhibition or by genetic modification of vaccine strains, is expected to reduce the pathogenic po

158 pulmonary infection with F. tularensis live vaccine strain, its production is tightly regulated by I

159 ure of the parental strain, whereas the live vaccine strain lacks diversity according to multiple ind

160 86.5 to 87.9% identities, respectively, with vaccine strain LaSota, indicative of considerable divers

161 a virulence factor of the F. tularensis live vaccine strain (LVS) and demonstrated that a DeltatolC m

162 racellular trafficking of F. tularensis Live Vaccine Strain (LVS) and LVS with disruptions of wbtDEF

163 from mice vaccinated with F. tularensis Live Vaccine Strain (LVS) and related attenuated strains, we

164 spiratory infection with the attenuated Live Vaccine Strain (LVS) and the highly virulent SchuS4 stra

165 Previous studies with the attenuated live vaccine strain (LVS) identified a role for the outer mem

166 of the F. tularensis subsp. holarctica live vaccine strain (LVS) in macrophages and epithelial cells

167 ntly available unlicensed F. tularensis live vaccine strain (LVS) is needed to protect against intent

168 protection, we created an F. tularensis live vaccine strain (LVS) mutant with a significantly increas

169 ined the transcriptional profile of the live vaccine strain (LVS) of F. tularensis grown in the FL83B

170 ificantly resistant to infection by the live vaccine strain (LVS) of F. tularensis Resistance is char

171 intradermal challenge of mice with the live vaccine strain (LVS) of F. tularensis, splenic IL-10 lev

172 f A549 airway epithelial cells with the live vaccine strain (LVS) of F. tularensis.

173 on against secondary challenge with the live vaccine strain (LVS) of Francisella tularensis.

174 del of pulmonary infection by using the live vaccine strain (LVS) of Francisella tularensis.

175 (IL-17) confers protection against the live vaccine strain (LVS) of Francisella.

176 First, inactivation of FTL_0325 from live vaccine strain (LVS) or FTT0831c from Schu S4 resulted i

177 macrophages infected with F. tularensis live vaccine strain (LVS) or the virulent SchuS4 strain are d

178 the lethality of primary F. tularensis live vaccine strain (LVS) pulmonary infection in mice that ar

179 rmal inoculation with the F. tularensis live vaccine strain (LVS) results in a robust Th1 response in

180 We employed Francisella tularensis live vaccine strain (LVS) to study mechanisms of protective i

181 4) as being important for F. tularensis live vaccine strain (LVS) virulence.

182 though an attenuated strain, dubbed the live vaccine strain (LVS), is given to at-risk laboratory per

183 infection with a Francisella attenuated live vaccine strain (LVS), which is under study as a human va

184 Live vaccine strain (LVS)-vaccinated rabbits were challenged

185 d deletion mutants of the F. tularensis live vaccine strain (LVS).

186 Overall, the data suggest that the HSV-1 VC2 vaccine strain may be used as a viral vector for the vac

187 bition of PA-X expression in influenza virus vaccine strains may provide a novel way of safely attenu

188 siblings; the proband developed disseminated vaccine strain measles following routine immunization, w

189 The efficacy of LAIV against vaccine-strain moderate-to-severe LCI was 56.7% (95% con

190 of the bunyaviruses Rift Valley fever virus (vaccine strain MP-12) and La Crosse virus (LACV).

191 However, due to antigenic drift, vaccine strains must be periodically updated.

192 However, as a result of antigenic drift, vaccine strains must be regularly updated to reflect cur

193 However, vaccine strains must be updated to reflect current strai

194 cobacterium tuberculosis with the attenuated vaccine strain Mycobacterium bovis bacillus Calmette-Gue

195 -type PPRV or either of two established PPRV vaccine strains, Nigeria/75/1 or Sungri/96.

196 eport the development of a poliovirus type 2 vaccine strain (nOPV2) that is genetically more stable a

197 e observed that a newly generated Salmonella vaccine strain not only conferred superior protection co

198 viruses (Yamagata and Victoria lineages) and vaccine strains occurs frequently.

199 de identity in all 10 genome segments with a vaccine strain of BTV-10 from the United States.

200 egments of RSArrrr/16 group closely with the vaccine strain of BTV-16 (RSAvvvv/16) that was derived f

201 cine.IMPORTANCE The live-attenuated Candid#1 vaccine strain of Junin virus is used to protect against

202 ld-type mice cleared Candid 1 (JUNV C1), the vaccine strain of Junin virus, more rapidly than did TLR

203 glycoprotein of the Candid#1 live-attenuated vaccine strain of JUNV in MACV replication and its abili

204 to Mycobacterium avium paratuberculosis; the vaccine strain of M. bovis Bacillus Calmette-Guerin; and

205 ip between bat mumps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chi

206 While sera from animals vaccinated with the vaccine strain of RPV showed cross-neutralizing ability

207 e markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotype Typhimuri

208 virus infection against not only historical vaccine strains of H3N2 but also a set of cocirculating

209 Edmonston vaccine strains of measles virus (MV) have significant a

210 induction was similar between wild-type and vaccine strains of MeV.

211 rotected from rinderpest by inoculation with vaccine strains of the related morbillivirus, peste des

212 Although VZV vaccine strain Oka is attenuated, it can cause mild vari

213 ABV expressing the attachment protein of CDV vaccine strain Onderstepoort succumbed to infection with

214 Salmonella may be useful as live attenuated vaccine strains or as vehicles for heterologous antigen

215 a virus subtypes to improve the stability of vaccine strains or components.

216 Wild type (live vaccine strain) or catalase-deficient F. tularensis (Del

217 e attenuated infectious bursal disease virus vaccine strain PBG98.

218 Using a dengue virus serotype 2 (DENV-2) vaccine strain (PDK53), we show that infection creates a

219 r alternative etiology and with isolation of vaccine-strain poliovirus.

220 ns exposed to the egg-adapted 2016-2017 H3N2 vaccine strain poorly neutralize a glycosylated clade 3C

221 tigenic distances: the distances between the vaccine strain, pre-existing immunity, and the challenge

222 king studies demonstrated uptake of the Bp82 vaccine strain predominately by neutrophils in vaccine-d

223 e top candidates dramatically improved viral vaccine strain production.

224 glycoprotein-deletion variant of the SAD-B19 vaccine strain rabies virus (RABV) has been the reagent

225 lent vaccine candidates based on recombinant vaccine strain rabies virus particles, which concurrentl

226 ive PCR [RT-qPCR]) that can identify measles vaccine strains rapidly, with high throughput, and witho

227 ating new pandemic 2009 virus; Arg226 in the vaccine-strain RBS accounts for the restriction.

228 ng mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE.

229 ommon ancestor, probably an ancient smallpox vaccine strain related to horsepox virus.

230 luenza vaccines mainly depends upon how well vaccine strains represent circulating viruses; mismatche

231 lier viruses and WHO-recommended prepandemic vaccine strains representing these clades.

232 eceiving LAIV, 45% and 67% shed A/H3N2 and B vaccine strains, respectively.

233 y, a genetic screen using the iglE-null live vaccine strain resulted in the identification of key reg

234 However, one post vaccine strain, RVA/Human-wt/RWA/UFS-NGS:MRC-DPRU442/201

235 lasts and infected with B. abortus 2308, the vaccine strain S19, and attenuated mutants S19vjbR and B

236 e significantly lower than those against the vaccine strain Sabin-1, two genetically distinct WPV1s i

237 porter gene expression, in contrast with the vaccine strain SAD.

238 ainst either a panel of viruses representing vaccine strains selected by the World Health Organizatio

239 l approaches that may complement the current vaccine strain selection process, we selected antigenic

240 res of influenza virus fitness could improve vaccine strain selection through more accurate forecasts

241 he antigenic match of hemagglutinin (HA) for vaccine strain selection, and most vaccines rely on HA i

242 To improve vaccine strain selection, human serologic testing on vac

243 on by traditional methods, thus complicating vaccine strain selection.

244 oncerns about vaccine effectiveness (VE) and vaccine strain selection.

245 s a valuable new antigenic analysis tool for vaccine strain selection.

246 to identify influenza antigenic variants for vaccine strain selection.

247 Importantly, these candidate vaccine strains showed strong protective efficacy agains

248 nuation purposes, generating the recombinant vaccine strains SLT17 (pCZ1) and SLT18 (pCZ1).

249 Rapid, vaccine strain-specific diagnostic assays will more effi

250 somewhat mitigated in combination with other vaccine strain-specific mutations, which might be compen

251 zing antibody) and/or stool excretion of the vaccine strain, stratified by HBGA status were determine

252 Live attenuated vaccine strains, such as type I nonreplicating uracil au

253 n=230; ranging from 29% to 65% for the three vaccine strains) than in the single-dose group (n=230; r

254 of two clones of VACV-IOC, a unique smallpox vaccine strain that contributed to smallpox eradication

255 , it has been a challenge to identify an RSV vaccine strain that has an optimal balance between atten

256 broad implications for rational selection of vaccine strains that do not contain prolines in antigeni

257 st the live attenuated West Nile virus (WNV) vaccine strain, the nonstructural (NS) 4B-P38G mutant.

258 ons, and for many live attenuated Salmonella vaccine strains, the acid tolerance response is unable t

259 Compared to common vaccine strains, the African strain contains a previousl

260 . tularensis subsp. holarctica (type B) live vaccine strains, thereby demonstrating the vaccine poten

261 uberculosis from the Bacille-Calmette-Guerin vaccine strain, they currently lack the specificity to d

262 The first comparison of a live RNA viral vaccine strain to its wild-type parental strain by deep

263 essed for the development of live-attenuated vaccine strains to combat HFAs.

264 le-genome sequencing of the M. gallisepticum vaccine strain ts-11 and several "ts-11-like" strains is

265 We also determined that vaccine strains ts-11 and 6/85 produce little to no H2O2

266 falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination.

267 -2D (LdWT) and characterized the LdCen (-/-) vaccine strain using bioinformatics tools.

268 that can be used for screening and selecting vaccine strains using immunoinformatics tools and a huma

269 05) to Brucella vaccine protection efficacy: vaccine strain, vaccination host (mouse) strain, vaccina

270 number and proportion of HZ cases caused by vaccine-strain varicella zoster virus (VZV), assessed th

271 , the majority (78%) captured the infectious vaccine strain virus (CM244), while a smaller proportion

272 lizing antibodies against tier 1 and tier 2 (vaccine strain) viruses.

273 The live, attenuated varicella vaccine strain (vOka) is the only licensed therapeutic v

274 rase chain reaction to identify wild-type or vaccine-strain VZV.

275 The Type B live vaccine strain was also 50% less capable of initiating s

276 Immunogenicity against the vaccine strain was assessed 21 days after the first and

277 nization with a live attenuated Burkholderia vaccine strain was dependent primarily on generation of

278 17D-204 was observed, demonstrating that the vaccine strain was derived by discrete mutation of Asibi

279 either cryopreservation or cell culture, the vaccine strain was maintained for decades by sequential

280 sive drift away from the A/California/7/2009 vaccine strain was observed at both the nucleotide and a

281 istinguishable from that of the 181/clone 25 vaccine strain was obtained by the simultaneous expressi

282 atch to circulating viruses, except when the vaccine strain was unchanged from the prior season.

283 Sequence divergence relative to vaccine strains was substantial, likely contributes to o

284 species barrier and to identify a candidate vaccine strain, we evaluated the in vitro and in vivo pr

285 , measles exposure and identification of the vaccine strain were helpful for public health decision-m

286 against the 2009 pandemic influenza A(H1N1) vaccine strain were significantly enhanced, compared wit

287 The vaccine strains were confirmed to be attenuated in vivo

288 ns during this era, but the chosen wild-type vaccine strains were not able to elicit antibodies with

289 These vaccine strains were tested for immunogenicity in Africa

290 ttenuated herpes simplex virus 1 (HSV-1) VC2 vaccine strain, which has been shown to be unable to ent

291 cidence of HZ cases from reactivation of the vaccine strain, which in the long term will likely outnu

292 HAI titers against the current A(H1N1)pdm09 vaccine strain, which lacks this mutation.

293 mmunity response in contrast to M protein of vaccine strains, which have lost this property.

294 virus is critical for accurate selection of vaccine strains, which is important for effective preven

295 3) season's B/Wisconsin/01/2010-like clade 3 vaccine strain, while only 17% clustered with the curren

296 ce immunized with the auxotrophic Salmonella vaccine strain with the deletion mutation Delta(wza-wcaM

297 In Salmonella vaccine strains with RDAS, the strain with the Delta(wza

298 lly similar to the A/California/07/2009-like vaccine strain, with an adjusted VE of 71% (95% confiden

299 We used the live attenuated vaccine strain YFV-17D, which contains many mutations co

300 4 (DENV1 to DENV4) and the yellow fever 17D vaccine strain (YFV-17D) did not antagonize STAT5 phosph